A Phase 2 interventional study of tamsulosin hydrochloride and solifenacin succinate in Lower Urinary Tract Symptoms and Prostatic Hyperplasia, sponsored by Astellas Pharma Inc. Completed at 98 sites in 16 countries. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2014-08-20.
Sponsored by Astellas Pharma Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing tamsulosin in Lower Urinary Tract Symptoms — 5 open to participants now, 5 under way, none of them phase 3. Tamsulosin · Lower Urinary Tract Symptoms.
Among the 22 studies testing tamsulosin in Lower Urinary Tract Symptoms, this one is the 4th largest by enrollment, is one of 3 that started in 2007, is one of 4 in phase 2, and was the 2nd registered.
417 studies on the registry are indexed under Lower Urinary Tract Symptoms; 110 are open to participants now.
Browse Lower Urinary Tract Symptoms studies →5 of the 22 studies testing tamsulosin in Lower Urinary Tract Symptoms are open now, in 4 countries. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Ages 45+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+ · Women only
Azienda Ospedaliero Universitaria Maggiore della Carita · Sites in Italy
Ages 40+ · Men only · Healthy volunteers
Ain Shams University · Sites in Egypt
Ages 50+ · Men only
Peking University First Hospital · Sites in China
Ages 40–85 · Men only
By country, each count listing its studies:
Tamsulosin: first FDA approval 1997 (FLOMAX). What it is approved for, and how studies give it, is on its page →
Of the 59 Lower Urinary Tract Symptoms studies recruiting now, 39 (66%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.
This study: 45 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4 · Phase 4 9
First in 2001; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 919 is above the median of 100 across 272 interventional studies indexed under Lower Urinary Tract Symptoms.
Median enrollment 136 across the 22 interventional studies. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 22 have an industry lead sponsor. The 10 most frequent:
Astellas Pharma Inc is the lead sponsor of 525 studies on the registry; 4 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 19 (68%) have results posted.
11 studies in Lower Urinary Tract Symptoms by Astellas Pharma Inc: none open now, none under way, none of them phase 3. Of 11 finished, 5 (45%) have results posted.
Among the 11 studies in Lower Urinary Tract Symptoms by Astellas Pharma Inc, this one is one of 3 that started in 2007, is one of 3 in phase 2, and was the 3rd registered.
Astellas Pharma Inc’s Lower Urinary Tract Symptoms studies by the year they started, since 2006.
1 of the studies testing tamsulosin in Lower Urinary Tract Symptoms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07722884Ain Shams UniversityTamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies testing tamsulosin in Lower Urinary Tract Symptoms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Astellas Pharma Inc’s 11 in Lower Urinary Tract Symptoms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will examine the efficacy,safety and tolerability of combination therapy of tamsulosin and solifenacin compared to placebo and monotherapy of tamsulosin and solifenacin in the treatment of males with LUTS associated with BPH.
Placebo Solifenacin succinate Tamsulosin hydrochloride Tamsulosin hydrochloride + solifenacin succinate
The primary comparison will be the combination treatment with tamsulosin hydrochloride monotherapy.
Other comparisons will be:
Placebo and combination treatment. Solifenacin monotherapy and combination treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Placebo
Drug: solifenacin succinate
Drug: solifenacin succinate
Drug: solifenacin succinate
Drug: tamsulosin hydrochloride
Drug: tamsulosin hydrochloride · Drug: solifenacin succinate
Drug: tamsulosin hydrochloride · Drug: solifenacin succinate
Drug: tamsulosin hydrochloride · Drug: solifenacin succinate
Alphablocker
antimuscarinic
Placebo
Assess whether the combination of solifenacin succinate and tamsulosin hydrochloride provides improved efficacy compared to tamsulosin hydrochloride alone in males with LUTS associated with BPH
Time frame: 12 weeks
Assess efficacy, safety, tolerability and PK of the combination of solifenacin succinate and tamsulosin hydrochloride
Time frame: 12 weeks
The record gives a start of Jan 2007, a primary completion of Sep 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tamsulosin · Solifenacin
Lower Urinary Tract Symptoms →